WebTrabectedin (Yondelis®) for the treatment of adult patients with advanced soft tissue sarcoma, after failure of anthracyclines and ifosfamide, or who are unsuited to receive … WebNov 22, 2024 · Trabectedin is a natural product derived from the Caribbean sea squirt which has antineoplastic activity and is used to treat soft tissue sarcoma. Trabectedin therapy is associated with a high rate of transient …
Yondelis European Medicines Agency
WebAbstract. Trabectedin (Yondelis); ET-743) is an antineoplastic agent that was originally derived from the Caribbean marine tunicate Ecteinascidia turbinata and is now produced synthetically. It binds to the minor groove of DNA, disrupting the cell cycle and inhibiting cell proliferation. Intravenous trabectedin administered once every 3 weeks ... WebFeb 23, 2024 · Trabectedin was administered at a dose of 1.5 mg/m 2, 24-h IV infusion every 3 weeks. The first of these studies was conducted in 54 advanced or metastatic STS patients with failure of prior chemotherapy ( Yovine et al., 2004 ). The objective response rate was 4%, although the disease control rate at 6 months was 24%. chronic-active
Trabectedin Drugs BNF NICE
WebTrabectedin is the generic name for the trade name drug Yondelis®. In some cases health care professionals may use the trade name Yondelis® when referring to the generic drug name trabectedin. Drug Type:Trabectedin is an anti-cancer ("antineoplastic" or "cytotoxic") chemotherapy drug. Trabectedin is classified as an "alkylating agent." WebAdminister dexamethasone 20 mg intravenously 30 minutes prior to each dose of YONDELIS®.1. Recommended starting dose and schedule1. The recommended dose … WebFeb 24, 2010 · Guidance. Evidence-based recommendations on trabectedin (Yondelis) for treating advanced soft tissue sarcoma in adults. In February 2024 we updated sections 1 and 2 of the guidance. This reflects changes to the commercial arrangement and the company holding the marketing and distribution rights to trabectedin in the UK. chronic acne treatment